Logo image of MCMJ

MERIDA MERGER CORP I (MCMJ) Stock Fundamental Analysis

NASDAQ:MCMJ - Nasdaq - Common Stock

6.53  +0.1 (+1.56%)

After market: 6.8 +0.27 (+4.13%)

Fundamental Rating

1

Overall MCMJ gets a fundamental rating of 1 out of 10. We evaluated MCMJ against 0 industry peers in the Unkown industry. The financial health of MCMJ is average, but there are quite some concerns on its profitability. MCMJ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MCMJ has reported negative net income.
MCMJ Yearly Net Income VS EBIT VS OCF VS FCFMCMJ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 0 -500K -1M -1.5M

1.2 Ratios

Industry RankSector Rank
ROA -4.8%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MCMJ Yearly ROA, ROE, ROICMCMJ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 0 -0.5 -1

1.3 Margins

MCMJ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MCMJ Yearly Profit, Operating, Gross MarginsMCMJ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020

More info and screens

5

2. Health

2.1 Basic Checks

MCMJ has less shares outstanding than it did 1 year ago.
MCMJ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MCMJ Yearly Shares OutstandingMCMJ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 5M 10M 15M
MCMJ Yearly Total Debt VS Total AssetsMCMJ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 7.86 indicates that MCMJ is not in any danger for bankruptcy at the moment.
MCMJ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.86
ROIC/WACCN/A
WACCN/A
MCMJ Yearly LT Debt VS Equity VS FCFMCMJ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 20M 40M 60M 80M 100M

2.3 Liquidity

MCMJ has a Current Ratio of 0.49. This is a bad value and indicates that MCMJ is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.49 indicates that MCMJ may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
MCMJ Yearly Current Assets VS Current LiabilitesMCMJ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 100K 200K 300K 400K 500K

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MCMJ have decreased strongly by -7423.97% in the last year.
EPS 1Y (TTM)-7423.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1082.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -0.62% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-87.12%
EPS Next 2Y-95.74%
EPS Next 3Y-32.32%
EPS Next 5Y-0.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MCMJ Yearly Revenue VS EstimatesMCMJ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 50M 100M 150M 200M
MCMJ Yearly EPS VS EstimatesMCMJ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MCMJ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MCMJ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MCMJ Price Earnings VS Forward Price EarningsMCMJ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MCMJ Per share dataMCMJ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as MCMJ's earnings are expected to decrease with -32.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-95.74%
EPS Next 3Y-32.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MCMJ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERIDA MERGER CORP I

NASDAQ:MCMJ (2/4/2022, 8:00:01 PM)

After market: 6.8 +0.27 (+4.13%)

6.53

+0.1 (+1.56%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.6%
Inst Owner Change0%
Ins Owners9.93%
Ins Owner Change0%
Market Cap106.91M
Analysts82.86
Price Target15.3 (134.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.49
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y1%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z 7.86
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7423.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1082.25%
EPS Next Y-87.12%
EPS Next 2Y-95.74%
EPS Next 3Y-32.32%
EPS Next 5Y-0.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A